HS-10241

News alerts, weekly reports and conference planners

Company:

Jiangsu Hansoh Pharma

Drug class:

c-MET inhibitor

Related drugs:

‹

›

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	aumolertinib + HS-10241 Sensitive: C2 – Inclusion Criteria aumolertinib + HS-10241 Sensitive : C2	aumolertinib + HS-10241 Sensitive: C2 – Inclusion Criteria aumolertinib + HS-10241 Sensitive : C2
EGFR mutation + MET amplification	Non Small Cell Lung Cancer	EGFR mutation + MET amplification	Non Small Cell Lung Cancer	aumolertinib + HS-10241 Sensitive: C3 – Early Trials aumolertinib + HS-10241 Sensitive : C3	aumolertinib + HS-10241 Sensitive: C3 – Early Trials aumolertinib + HS-10241 Sensitive : C3

Associations
(2)